Cardiff Oncology
Eric Van Cutsem, MD, PhD, is full professor and division head of digestive oncology at University of Leuven (KUL) and University Hospitals Gasthuisberg, in Leuven, Belgium. He is a member of the Belgian Royal Academy of Medicine and president of the Belgian Foundation Against Cancer. Dr. Van Cutsem’s research focuses on the development of new treatment strategies for gastrointestinal (GI) cancers, including drug development and identification of molecular markers and diagnostic tools. He co-founded ESMO GI/World Congress on Gastrointestinal Cancer and serves/served on the board or key committees of the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), European Neuroendocrine Tumor society (ENET), the European Organisation for Research and Treatment of Cancer (EORTC), European Society o Digestive Oncology (ESDO) and of the patient advocacy groups EuropaColon and Digestive Cancers Europe.
This person is not in the org chart
This person is not in any offices
Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.